Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06030076 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study to Assess the Effects of Switching From a Biologic Treatment to Tildrakizumab Using Patient-reported Outcomes in Adult Participants With Moderate to Severe Plaque Psoriasis

StatusRecruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated January 29, 2025 (before its estimated October 2025 completion). Its status may not reflect the trial's current state.

Record History

  1. Primary and study completion dates: Jan 2025 to Oct 2025v3
  2. Trial status: Not Yet Recruiting to Recruiting Start date changed from estimate of Sep 15, 2023 to Sep 6, 2023v2 Show 1 more changeShow less
    • Start date changed from estimate of Sep 15, 2023 to Sep 6, 2023
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Almirall, S.A.
15 trials monitored
See all monitored trials
Psoriasis
420 trials monitored
See 17 trials at risk
The main aim of this study is to assess the effects of switching from another biologic to tildrakizumab on patient-reported outcomes and to assess psoriasis intensity, patient's quality of life prior and after switching and the individual rationales for switching biologics.
Trial Details
NCT Number NCT06030076
Lead Sponsor Almirall, S.A.
Conditions Plaque Psoriasis
Enrollment 50 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov